Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results

Biomea Fusion, Inc. (NASDAQ:BMEA) earns a place on our list of the top 10 stocks under $5 that could triple. Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results As of March 19, 2026, almost 88% of covering analysts keep bullish ratings on the stock. With a consensus price target of $6.00, indicating a potential upside of 415.02%, analyst sentiment remains positive toward Biomea Fusion, Inc. (NASDAQ:BMEA). On March 14, 2026, Biomea Fusion, Inc. (NASDAQ:BMEA) repor ...